facebook pixel

Jason Hawkes, MD MS FAAD

Dr. Jason Hawkes is a board-certified dermatologist and Associate Professor of Dermatology at the University of California Davis. He received his Medical Degree from the University of Utah School of Medicine. During medical school, he was selected for a one-year research fellowship year at the National Institutes of Health as part of the Howard Hughes Medical Institute Research Scholars Program. He completed his internship in internal medicine at the University of Washington/Boise VA Medical Center. He returned to the University of Utah School of Medicine for his dermatology residency training and graduated from the Program’s 2+2 Translational Research Track. He then completed a Master’s Degree in Clinical Investigation at the Rockefeller University in New York City, where he was also the Chief Clinical Scholar and member of the Laboratory for Investigative Dermatology. Dr. Hawkes was also a Clinical Instructor in the Department of Dermatology in the Icahn School of Medicine at Mount Sinai, where he saw patients and taught residents, fellows, and physician assistants.
Dr. Hawkes has served as the Principal Investigator and Co-Investigator of multiple pharmaceutical-sponsored and investigator-initiated clinical trial protocols. He is also currently serving on the Medical Board of the National Psoriasis Foundation and is the recipient of multiple teaching awards. He is the author of more than 40 peer-reviewed publications and 6 book chapters. He is a Fellow of the American Academy of Dermatology and is a member of multiple national and international organizations, including the National Psoriasis Foundation, Dermatology Foundation, and Society of Investigative Dermatology. His research has previously been funded by the Dermatology Foundation, Melanoma Research Foundation, National Psoriasis Foundation, and National Institutes of Health. Dr. Hawkes’ principal clinical and research interests are the treatment of complex inflammatory diseases, such as psoriasis and eczema, using novel, targeted systemic or biologic therapies.